Baird R W Upgrades DexCom (NASDAQ:DXCM) to Strong-Buy

Baird R W upgraded shares of DexCom (NASDAQ:DXCM - Free Report) from a hold rating to a strong-buy rating in a research note released on Thursday,Zacks.com reports.

A number of other equities analysts also recently issued reports on DXCM. JPMorgan Chase & Co. lifted their price target on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. Canaccord Genuity Group lifted their target price on DexCom from $89.00 to $99.00 and gave the company a "buy" rating in a research report on Monday, December 9th. Citigroup upped their price target on DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Wells Fargo & Company raised their price objective on DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. Finally, Royal Bank of Canada reduced their target price on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $99.29.

DexCom Stock Down 0.5 %

Shares of NASDAQ DXCM traded down $0.46 during mid-day trading on Thursday, reaching $84.38. 5,134,065 shares of the company's stock traded hands, compared to its average volume of 3,952,632. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The business has a 50-day simple moving average of $78.17 and a 200 day simple moving average of $78.22. The stock has a market cap of $32.96 billion, a P/E ratio of 50.53, a PEG ratio of 2.00 and a beta of 1.12. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company's stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.30% of the stock is owned by corporate insiders.

Institutional Trading of DexCom

Hedge funds and other institutional investors have recently modified their holdings of the business. Blue Whale Capital LLP grew its stake in DexCom by 91.9% in the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock valued at $15,821,000 after buying an additional 113,000 shares in the last quarter. Taylor Frigon Capital Management LLC boosted its holdings in shares of DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company's stock worth $2,182,000 after acquiring an additional 11,075 shares during the period. Brooktree Capital Management purchased a new position in shares of DexCom in the third quarter valued at $683,000. National Pension Service raised its stake in shares of DexCom by 4.1% during the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company's stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. purchased a new stake in DexCom during the 3rd quarter worth about $650,000. Institutional investors own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.